A multidisciplinary panel discusses the effects of GLP-1 RA use during breast cancer care along with insurance denials, costs, and other critical areas.

First-line pembrolizumab monotherapy did not significantly improve overall survival vs carboplatin plus paclitaxel at the first analysis in dMMR advanced or recurrent endometrial cancer. In the TOP-1 ...

At the Big Ten CRC Summit, VK Gadi, MD, PhD, explained why functional drug testing and genomic profiling should be used ...

First-line pembrolizumab monotherapy did not significantly improve overall survival vs carboplatin plus paclitaxel at the first analysis in dMMR advanced or recurrent endometrial cancer.

Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after platinum and immunotherapy.

Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point. Although the phase 2 EVITA trial ...

The investigators concluded that AZUR-1 “demonstrates sustained clinical complete responses after dostarlimab monotherapy in ...

Sone-Ve significantly improved OS vs investigator’s choice in previously treated CLDN18.2-positive gastroesophageal carcinoma ...

Long-term PEACE-1 data showed that adding abiraterone acetate plus prednisone to standard of care extended median OS by 1.5 years in de novo metastatic CSPC. At the 2026 European Society for Medical ...

Translating laboratory discoveries into clinical benefit for patients with breast cancer increasingly depends on combining ...

The next-generation KRAS G12C inhibitor divarasib significantly prolonged progression-free survival (PFS) and overall ...

Congress, 3 proffered paper presentations examined treatment strategies across the renal cell carcinoma (RCC) continuum. LITESPARK-012: in the frontline setting, adding belzutifan (Welireg) or ...